Last reviewed · How we verify
NCT05274191
An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors
Phase 2 trial testing Pyrotinib Maleate in Solid Tumor in 60 participants. Status unknown.
15 March 2022
Quick facts
| Lead sponsor | Zhongshan Hospital Xiamen University |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 4 March 2022 |
| Primary completion | 15 March 2022 |
| Estimated completion | 15 March 2024 |
Drugs / interventions tested
- Pyrotinib Maleate
- standard regimen
Conditions studied
- Solid Tumor — all drugs for Solid Tumor →
Sponsor
Zhongshan Hospital Xiamen University
Who can join
Adults 18 to 75, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A single arm, open-label Phase II clinical study.The subjects were patients with lung, gastric and colorectal cancers.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates.
Kim J, Kim HS, Nam M, Chae YK. · · 2025 · cited 3× · PMID 40576713 · DOI 10.1007/s10555-025-10274-2
Verify or expand the search:
- PubMed search for NCT05274191
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pyrotinib Maleate
Trials testing the same drug.
- NCT05328440 — Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02) · Phase 2 · unknown
- NCT04903652 — Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer · Phase 2 · completed
- NCT04680091 — Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer · Phase 1 · unknown
- NCT03574402 — Phase II Umbrella Study Directed by Next Generation Sequencing · Phase 2 · unknown
Other recruiting trials for Solid Tumor
Currently open trials in the same condition.
- NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
- NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
- NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting
Other Zhongshan Hospital Xiamen University trials
Trials by the same sponsor.
- NCT07212569 — Analysis of Differences in Small Intestinal Microbiota Structure and Metabolites Between Patients With Irritable Bowel S · not yet recruiting
- NCT07045883 — Mechanism and Application of Vitamin D in Idiopathic Sudden Sensorineural Hearing Loss · NA · active not recruiting
- NCT06530069 — Exploring the Risk Factors of Otomycosis: A Case-Control Study · recruiting
- NCT06431542 — Efficacy of Self Vs. Physician Application of Triamcinolone-Econazole in Otomycosis · Phase 4 · completed
- NCT05637021 — Effect of Carbon Dioxide Insufflation and Appendix on the Restoration of Intestinal Microecology After Colonoscopy. · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05274191 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongshan Hospital Xiamen University
- Last refreshed: 10 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05274191.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing